Efficacy of Sonazoid (Perflubutane) for Contrast-Enhanced Ultrasound in the Differentiation of Focal Breast Lesions: Phase 3 Multicenter Clinical Trial

Miyamoto, Yukio; Ito, Toshikazu; Takada, Etsuo; Omoto, Kiyoka; Hirai, Toshiko; Moriyasu, Fuminori

doi:10.2214/ajr.12.10518

Cited by 81 publications

(53 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sonazoid ® microbubbles were shown to improve the accuracy of diagnosis of prostate cancer, which could reduce the number of biopsies patients need to receive to achieve a similar diagnostic result 31 . In Japan, Sonazoid ® was also used in a phase III clinical trial to compare its diagnostic potential of focal breast lesions against unenhanced ultrasound and contrast enhanced MRI (Figure 2) 32 . The study found that while CEUS technology did not statistically significantly increase the sensitivity of the diagnosis, it substantially enhanced the accuracy and specificity at a reduced cost 32 .…”

Section: Clinical Applications Of Ultrasound Contrast Agentsmentioning

confidence: 99%

Ultrasound imaging beyond the vasculature with new generation contrast agents

Perera

Hernandez

Zhou

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Current commercially available ultrasound contrast agents are gas-filled, lipid- or protein-stabilized microbubbles larger than 1 μm in diameter. Because the signal generated by these agents is highly dependent on their size, small yet highly echogenic particles have been historically difficult to produce. This has limited the molecular imaging applications of ultrasound to the blood pool. In the area of cancer imaging, microbubble applications have been constrained to imaging molecular signatures of tumor vasculature and drug delivery enabled by ultrasound-modulated bubble destruction. Recently, with the rise of sophisticated advancements in nanomedicine, ultrasound contrast agents, which are an order of magnitude smaller (100-500 nm) than their currently utilized counterparts, have been undergoing rapid development. These agents are poised to greatly expand the capabilities of ultrasound in the field of targeted cancer detection and therapy by taking advantage of the enhanced permeability and retention phenomenon of many tumors and can extravasate beyond the leaky tumor vasculature. Agent extravasation facilitates highly sensitive detection of cell surface or microenvironment biomarkers, which could advance early cancer detection. Likewise, when combined with appropriate therapeutic agents and ultrasound-mediated deployment on demand, directly at the tumor site, these nanoparticles have been shown to contribute to improved therapeutic outcomes. Ultrasound's safety profile, broad accessibility and relatively low cost make it an ideal modality for the changing face of healthcare today. Aided by the multifaceted nano-sized contrast agents and targeted theranostic moieties described herein, ultrasound can considerably broaden its reach in future applications focused on the diagnosis and staging of cancer.

show abstract

Section: Clinical Applications Of Ultrasound Contrast Agentsmentioning

confidence: 99%

Ultrasound imaging beyond the vasculature with new generation contrast agents

Perera

Hernandez

Zhou

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…For example, metastasis has been successfully diagnosed in axillary lymph nodes of patients with breast cancer using Sonazoid TM (28). Clinical trials are currently being performed, aiming to differentiate benign and malignant focal lesions in the breast (29). The present study shows a possible application for Sonazoid TM in CRC.…”

Section: A B C D E F G Hmentioning

confidence: 72%

Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer

Tomizawa

Togashi

Shinozaki

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that CEUS is useful for differentiating between benign and malignant breast lesions [1,2], evaluating the disease extent [3,4], and assessing the tumor response after neoadjuvant chemotherapy [5,6].…”

Section: Introductionmentioning

confidence: 99%